Glutathione

Glutathione (GSH) is a tripeptide consisting of γ-L-glutamyl-L-cysteinyl-glycine. It is the most abundant low-molecular-weight thiol in mammalian cells and the central nonenzymatic antioxidant in human biology. The reduced form (GSH) cycles to the oxidized form (GSSG) by donating electrons to neutralize reactive oxygen species, then back to GSH via glutathione reductase using NADPH. The GSH-to-GSSG ratio is a standard biomarker of cellular redox state.

The molecule has a molecular weight of 307.3 g/mol. Its three amino acids are linked by an unusual γ-bond between glutamate and cysteine, which gives glutathione resistance to most proteases but not to γ-glutamyltransferase (γ-GT) and dipeptidases at intestinal and other mucosal surfaces. That detail is the entire reason oral glutathione bioavailability is a contested topic.

The Synthesis Pathway

Glutathione is synthesized intracellularly in two steps. The first reaction joins glutamate to cysteine via γ-glutamylcysteine synthetase (GCS), also called glutamate-cysteine ligase. This step is rate-limiting and feedback-inhibited by GSH itself. The second reaction adds glycine via glutathione synthetase. Cysteine availability is the practical bottleneck under most conditions, which is why N-acetylcysteine (NAC) supplementation reliably raises cellular GSH and why oral glutathione typically does not raise it as effectively.

The liver is the highest-output site, synthesizing roughly 10 g of GSH per day in a healthy adult. Plasma concentrations are tightly regulated (1-10 μM) compared with intracellular levels (1-10 mM), maintained by hepatic export and uptake by other tissues.

The Bioavailability Problem

Standard oral glutathione is partially hydrolyzed in the gut. γ-glutamyltransferase on the intestinal brush border cleaves the γ-bond. The component amino acids are absorbed and re-synthesized into GSH inside cells. The net effect is that 250 mg of standard oral GSH does less to raise intracellular GSH than an equivalent dose of cysteine or NAC.

Liposomal and micellar formulations have been developed to partially solve this. The LipoMicel trial published in MDPI Antioxidants in 2026 compared a novel micellar GSH formulation (LMG) against standard GSH and an existing liposomal product (LSG) in 14 healthy adults. At dose-normalized 300 mg, LMG showed a significantly higher GSH-to-GSSG ratio than standard GSH (p = 0.001) and a 4.58-fold higher methionine exposure. Over 30 days at 600 mg per day, the formulation was well-tolerated with no significant changes in ALT, AST, ALP, or creatinine.

The unresolved issue across all of these trials is whether elevated whole-blood GSH reflects increased GSH in cells where antioxidant work happens, or whether it simply increases plasma and red-cell glutathione without reaching the tissues that need it. Cellular bioavailability studies remain rare and methodologically difficult.

Regulatory and Legal Status

In the United States, oral glutathione is sold as a dietary supplement. It is not an FDA-approved drug. Compounded sterile injectable glutathione exists at 503A and 503B compounding pharmacies. In June 2019, the FDA issued a communication raising concerns about the practice, specifically that dietary-ingredient (non-pharmaceutical-grade) glutathione was being used to compound sterile injectables without adequate sourcing and quality controls.

Cosmetic skin-lightening use is the highest-risk regulatory niche. The FDA has not approved any glutathione product for skin whitening. A US federal court ordered Flawless Beauty in New Jersey to stop distributing unapproved skin-whitening injectables containing glutathione. The Philippines FDA issued Advisory 2019-182 warning that injectable glutathione for skin lightening carries risks of liver, kidney, and nervous-system toxicity, Stevens-Johnson syndrome, and infection from non-sterile preparation. Several Asian countries have banned or restricted the cosmetic use entirely.

Inhaled glutathione is used off-label in cystic fibrosis to help break down mucus. It is not FDA-approved for this purpose.

Glutathione is not on the WADA Prohibited List. Use in sport is permitted.

Glutathione's antioxidant function works through two routes.

Direct reduction: GSH donates a hydrogen atom from its cysteine sulfhydryl group to neutralize a reactive oxygen species (ROS) or a reactive nitrogen species (RNS). Two GSH molecules combine to form GSSG (oxidized glutathione disulfide) in the process. GSSG is then recycled back to GSH by glutathione reductase using NADPH as the electron donor. This cycle is tight in healthy cells. When oxidative stress overwhelms the system, GSH/GSSG ratio drops, which is itself a measurable biomarker of dysfunction.

Enzymatic substrate role: GSH is the substrate for several glutathione peroxidase (GPx) enzymes, particularly GPx1 (cytosolic) and GPx4 (membrane-associated). GPx enzymes catalyze the reduction of hydrogen peroxide and lipid peroxides to water and alcohols, respectively. GPx4 specifically protects against ferroptosis, a form of iron-dependent regulated cell death.

GSH also functions as a cofactor for glutathione S-transferases (GSTs), which conjugate glutathione to electrophilic xenobiotics (drugs, environmental toxins, products of oxidative damage) as part of Phase II detoxification. The resulting GSH-conjugates are exported and excreted. This is why acetaminophen overdose treatment uses NAC: to replenish hepatic GSH so that the toxic acetaminophen metabolite NAPQI can be detoxified before it depletes the liver.

A third functional role is glutathionylation of protein cysteines, a post-translational modification that regulates the activity of dozens of enzymes including caspases, kinases, and transcription factors. Glutathionylation can be reversed by glutaredoxin (Grx) systems.

For melanin biology, GSH affects the tyrosinase pathway in melanocytes. Reduced glutathione interferes with the polymerization of dopaquinone, the tyrosinase substrate, and shifts melanin synthesis from eumelanin (dark brown/black) toward pheomelanin (red/yellow), which is lighter in appearance. This is the mechanistic basis for the skin-lightening claim, and it is biologically real. The clinical question is whether the shift is dose-controllable, durable, and safe at the dose levels involved.

Pharmacokinetic data on intravenous GSH: peak plasma concentrations rise dramatically after a 600-1,200 mg dose, with a plasma half-life on the order of minutes (the molecule is rapidly degraded by γ-GT on endothelial surfaces). Most circulating GSH-equivalent mass is in the form of degradation products (cysteine, glycine, free GSH) within an hour of infusion.

Standard medical use of glutathione is narrow. It is given off-label as a mucolytic (inhaled) in cystic fibrosis, as part of paraquat poisoning protocols, and as adjunctive therapy in cisplatin chemotherapy in some jurisdictions (notably the Philippines, where it is approved for this).

Broader claimed effects in supplement and clinic use include:

• Anti-aging and longevity: based on the documented age-related decline in cellular GSH/GSSG ratio. No human trial has shown that exogenous glutathione reverses aging biomarkers in a meaningful way.
• Skin lightening: reported in IV studies at high doses (1,200 mg twice weekly). Effects are transient. Safety risks dominate the published evidence.
• Detoxification: theoretical basis is strong via GST conjugation. Clinical evidence for "detox" protocols is essentially absent at the controlled-trial level.
• Hangover, post-drinking recovery: anecdotal. The mechanism (acetaldehyde is a glutathione-depleting electrophile) is plausible. Controlled human data is sparse.
• Liver support, fatty liver: animal data is supportive. Human trials in non-alcoholic fatty liver disease have used NAC more than GSH itself, with modest results.
• Autism spectrum support: a recurring claim in the alternative-medicine world. No adequately-sized randomized trial supports specific GSH supplementation as an effective intervention.

The most controlled human work on oral GSH is the LipoMicel 2026 pharmacokinetic and safety trial, which demonstrated improved whole-blood GSH/GSSG ratio but did not measure clinical functional outcomes.

Oral glutathione doses in published trials range from 250 mg to 1,000 mg per day. The LipoMicel trial used 300 mg single doses for pharmacokinetics and 600 mg per day for 30-day safety. The Setria/Kyowa Hakko clinical trials with their liposomal product have used 250 mg and 1,000 mg per day in 6-month randomized comparisons, with both doses raising blood GSH biomarkers.

Intravenous glutathione in clinical use ranges from 600 mg to 3,000 mg per session. The Zubair trial used 1,200 mg IV twice weekly. Skin-lightening clinic protocols circulate 600-1,800 mg IV given 1-2 times weekly for 4-12 weeks. None of these regimens has been established by controlled trial as safe or efficacious for that purpose.

Inhaled glutathione for cystic fibrosis uses 66-600 mg nebulized doses, off-label, with limited clinical trial support.

N-Acetylcysteine (NAC) as an indirect GSH precursor is dosed at 600-1,800 mg per day orally in most studies. NAC is FDA-approved for acetaminophen overdose (IV dosing in the hundreds of mg/kg range) and as a mucolytic.

γ-Glutamyl-cysteine (GGC), marketed as Glyteine, is dosed at 200-700 mg per day. Single-dose human studies report rises in white blood cell GSH within 2 hours.

The recurring caveat across all these doses: blood GSH and tissue GSH are not the same thing. A dose that doubles whole-blood GSH may or may not raise GSH in liver, brain, heart, or skin. Direct tissue GSH measurement in humans requires biopsy and is rarely done outside of research settings.

Oral glutathione at supplement doses is well-tolerated in published trials. The 30-day LipoMicel safety phase reported no significant changes in liver enzymes (ALT, AST, ALP), creatinine, or other clinical safety markers at 600 mg per day. Mild gastrointestinal symptoms (nausea, bloating) appear occasionally at doses above 1 g per day.

Intravenous glutathione carries the bulk of the documented adverse-event profile.

The Zubair trial of 1,200 mg IV GSH twice weekly reported adverse events in 32 percent of participants. Documented events included liver dysfunction (elevated ALT and AST), allergic reactions ranging from urticaria to anaphylaxis, and dyspnea.

A 2025 case report described systemic inflammatory response syndrome (SIRS) with fever above 41°C, acute liver injury, and clotting abnormalities after a high-dose unregulated cosmetic infusion. The investigators suspected endotoxin contamination or supraphysiological dosing in a nutritionally compromised host.

Other reported risks across IV-glutathione case reports and the Philippines FDA Advisory include Stevens-Johnson syndrome, kidney stones (particularly when combined with high-dose IV vitamin C in acid urine), hemolytic anemia in G6PD-deficient patients, infection transmission (HIV, hepatitis B, hepatitis C) from non-sterile preparation in unlicensed clinic settings, and theoretical concerns about long-term skin cancer risk from sustained shifts in melanin synthesis away from photoprotective eumelanin.

The infection-transmission risk is not theoretical. Several documented outbreaks of hepatitis from non-sterile cosmetic injection clinics have been reported in Southeast Asia.

The bottom line on IV glutathione safety: at the doses used in supervised clinical studies for medical indications, it appears reasonably well tolerated. At the doses used in unregulated cosmetic clinics, with variable product quality and variable injection technique, the safety profile is substantially worse.

Glutathione is mechanistically paired with other antioxidants more than with peptide compounds. The pairing with N-acetylcysteine (NAC) is the most logical at the mechanism level, because NAC supplies cysteine, the limiting substrate for GSH synthesis. Many longevity protocols use NAC as the primary GSH-raising intervention and oral GSH as adjunctive.

The pairing with alpha-lipoic acid (ALA) is biochemically reasonable: ALA participates in mitochondrial redox cycling and helps regenerate other antioxidants including vitamin C and vitamin E, which in turn spare GSH consumption.

The pairing with NAD+ addresses the substrate side of redox balance: NADPH (which regenerates GSH from GSSG) is downstream of NAD+. Sustaining NADPH supply theoretically supports the GSH recycling system. The clinical trials testing this synergy in humans do not exist at scale.

The pairing with SS-31 addresses mitochondrial redox at a different layer: SS-31 reduces cardiolipin peroxidation directly at the inner mitochondrial membrane, while GSH operates throughout the cytosol and nucleus. No head-to-head or combined trial has been done.

The pairing with intravenous vitamin C is the most discussed and the most cautioned-against. The combination is widely used in IV-drip wellness clinics, particularly for "Myers cocktail"-style infusions. The risks identified by the Philippines FDA include kidney stone formation in acidic urine and hemolysis in G6PD-deficient patients. This is not a stack to enter casually.

The pairing that does not work is oral GSH with strong gut γ-GT activity. If the goal is to raise intracellular GSH, oral cysteine, NAC, or GGC will reach the target more efficiently than oral GSH itself.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.